Related Experiment Video
Updated: Aug 9, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
[Diabetes mellitus and coronary artery disease--a high risk combination]
V Schächinger1, M B Britten, A M Zeiher
1J. W. Goethe-Universität Frankfurt, Medizinische Klinik III/Kardiologie, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. schaechinger@em.uni-frankfurt.de
Insights
Diabetic patients face higher cardiovascular risk. Effective management requires considering factors beyond glucose control, including HbA1c, comorbidities, and medications for optimal treatment outcomes in coronary artery disease.
Area of Science:
- Cardiology
- Endocrinology
- Clinical Trials
Background:
- Diabetes mellitus is often underdiagnosed in routine clinical practice and underrepresented in clinical trials.
- Patients with diabetes exhibit increased cardiovascular risk across all stages and interventions of coronary artery disease (CAD).
- Individualizing diabetes management is crucial, as risk is modified by factors like HbA1c levels, comorbidities, and medications.
Purpose of the Study:
- To highlight the importance of diagnosing and characterizing diabetes in CAD patients.
- To discuss the prognostic value of HbA1c and the enhanced benefit of pharmacological therapies in diabetic patients.
- To review the efficacy of various interventions, including percutaneous coronary interventions (PCI) and pharmacological treatments, in diabetic individuals with CAD.
Main Methods:
- Review of current recommendations for diagnosing diabetes in CAD patients (fasting glucose, HbA1c).
- Analysis of the impact of diabetes on cardiovascular risk and treatment benefits.
- Evaluation of evidence for interventions like glycoprotein IIb/IIIa inhibitors, Clopidogrel, glitazones, drug-eluting stents, and glucose-insulin-potassium (GIK) infusion.
Main Results:
- HbA1c provides significant prognostic information in CAD patients.
- Pharmacological therapies, particularly statins and antihypertensives, show enhanced benefits in diabetic patients.
- Glycoprotein IIb/IIIa inhibitors and potentially Clopidogrel reduce mortality during PCI in diabetics; glitazones may reduce restenosis.
- Hyperglycemia during acute coronary syndrome is a negative prognostic marker, but GIK infusion benefits remain unproven.
Conclusions:
- Diabetes significantly increases cardiovascular risk, necessitating routine screening and characterization in CAD patients.
- Risk-modifying factors and comorbidities are critical for tailoring treatment strategies.
- While some interventions show promise, further research is needed to optimize outcomes, especially regarding drug-eluting stents and comparisons between PCI and bypass surgery.
Abstract:
Patients with diabetes mellitus are often not recognized in clinical routine, but also not well characterized in clinical trials. As a diagnostic approach it is recommended to test fasting glucose and glycosylated hemoglobin (HbA1c) in every patient with coronary artery disease (CAD). HbA1c, in addition, provides important prognostic information. Patients with diabetes mellitus do have an enhanced cardiovascular risk in all stages and during all kind of interventions of CAD. However, diabetes is not equal to diabetes; risk modifying factors such as HbA1c, concomitant diseases and medication have to be considered. Absolute benefit of pharmacological therapies is also enhanced in patients with diabetes compared to non-diabetics. However, statins or anti-hypertensive treatment seem to be even more effective in reducing cardiovascular events than pure control of glucose levels alone. During percutaneous interventions (PCI) glycoprotein IIb/IIIa-inhibitors reduce mortality in diabetics, an effect which may be partially also achieved by Clopidogrel. Glitazones reduce restenosis rates; however, clinical end point studies are still ongoing. After PCI, restenosis may be a predictor of mortality in patients with diabetes. Whether drug eluting stents, besides effectively reducing restenosis, may also reduce hard clinical events in patients with diabetes remains to be demonstrated. Current available studies comparing PCI with bypass are limited due to not considered factors (stenosis morphology), randomization bias, and faster progress of technology compared to study termination. During an acute coronary syndrome/myocardial infarction, hyperglycemia is an adverse prognostic marker. However, so far studies using glucose-insulin-potassium (GIK) infusion have not been convincingly demonstrate to be beneficial.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
01:30Coronary Artery Disease I: Introduction
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures
01:24Type II Diabetes II: Pathophysiology
01:22Complications of Diabetes Mellitus